Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection.
ME Laird,
A Mohsen,
D Duffy,
R Mamdouh,
L LeFouler,
A Casrouge,
M El-Daly,
M Rafik,
M Abdel-Hamid,
Alexandre SOULIER,
Jean-Michel PAWLOTSKY,
Christophe HEZODE,
I Rosa,
P Renard,
MK Mohamed,
P Bonnard,
J Izopet,
V Mallet,
S Pol,
ML Albert,
A Fontanet,
J Hepatol. 01/10/2014;61(4) : 770-776 10.1016/j.jhep.2014.05.040 04/06/2014
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
C Laouenan,
P Marcellin,
M Lapalus,
F Khelifa-Mouri,
N Boyer,
F Zoulim,
L Serfaty,
JP Bronowicki,
M Martinot-Peignoux,
O Lada,
T Asselah,
C Dorival,
Christophe HEZODE,
F Carrat,
F Nicot,
G Peytavin,
F Mentre,
J Guedj,
Antimicrob Agents Chemother. 01/09/2014;58(9) : 5332-5341 10.1128/AAC.02611-14 30/06/2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
ZM Younossi,
M Stepanova,
S Zeuzem,
G Dusheiko,
R Esteban,
Christophe HEZODE,
HW Reesink,
O Weiland,
F Nader,
SL Hunt,
J Hepatol. 01/08/2014;61(2) : 228-234 10.1016/j.jhep.2014.04.003. 05/04/2014
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Christophe HEZODE,
H Fontaine,
C Dorival,
F Zoulim,
D Larrey,
V Canva,
V De Ledinghen,
T Poynard,
D Samuel,
M Bourliere,
L Alric,
JJ Raabe,
JP Zarski,
P Marcellin,
G Riachi,
PH Bernard,
V Loustaud-Ratti,
O Chazouilleres,
A Abergel,
D Guyader,
S Metivier,
A Tran,
V Di Martino,
X Causse,
T Dao,
D Lucidarme,
I Portal,
P Cacoub,
J Gournay,
V Grando-Lemaire,
P Hillon,
P Attali,
T Fontanges,
I Rosa,
V Petrov-Sanchez,
Y Barthe,
Jean-Michel PAWLOTSKY,
S Pol,
F Carrat,
JP Bronowicki,
Gastroenterology 01/07/2014;147(1) : 132-142 10.1053/j.gastro.2014.03.051 03/04/2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
F Poordad,
Christophe HEZODE,
R Trinh,
KV Kowdley,
S Zeuzem,
K Agarwal,
ML Shiffman,
H Wedemeyer,
T Berg,
EM Yoshida,
X Forns,
SS Lovell,
B Da Silva-Tillmann,
CA Collins,
AL Campbell,
T Podsadecki,
B Bernstein,
N Engl J Med. 22/05/2014;370(21) : 1973-1982 10.1056/NEJMoa1402869. 11/04/2014
Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
S Zeuzem,
G Dusheiko,
R Salupere,
A Mangia,
R Flisiak,
RH Hyland,
A Illeperuma,
E Svarovskaia,
DM Brainard,
WT Symonds,
GM Subramanian,
JG McHutchison,
O Weiland,
HW Reesink,
P Ferenci,
Christophe HEZODE,
R Esteban,
N Engl J Med. 22/05/2014;370(21) : 1993-2001 10.1056/NEJMoa1316145. 04/05/2014
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
AS Lok,
DF Gardiner,
Christophe HEZODE,
EJ Lawitz,
M Bourliere,
GT Everson,
P Marcellin,
M Rodriguez-Torres,
S Pol,
L Serfaty,
T Eley,
SP Huang,
J Li,
M Wind-Rotolo,
F Yu,
F McPhee,
DM Grasela,
C Pasquinelli,
J Hepatol. 01/03/2014;60(3) : 490-499 10.1016/j.jhep.2013.10.019 26/10/2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.
S Zeuzem,
T Berg,
E Gane,
P Ferenci,
GR Foster,
MW Fried,
Christophe HEZODE,
GM Hirschfield,
I Jacobson,
I Nikitin,
PJ Pockros,
F Poordad,
J Scott,
O Lenz,
M Peeters,
V Sekar,
G De Smedt,
R Sinha,
M Beumont-Mauviel,
Gastroenterology 01/02/2014;146(2) : 430-441.e6 10.1053/j.gastro.2013.10.058. 01/11/2013
